Moffitt Cancer Center: Clinical Trial 20040

RESEARCH

Call Today

1-888-663-3488

Moffitt Notice of Blackbaud Data Incident. Learn More

Facebook

Twitter

Linkedin

Pinterest

Email

Clinical Trials Search

Back to Search Results

Clinical Trial 20040

Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT03712605

Phase: Phase III
Prinicipal Investigator: Andrew Brohl

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Summary

Objective

To compare Overall Survival (OS) and Recurrence Free Survival (RFS) as co-primary endpoints across the two arms. To evaluate adverse events. To evaluate Distant Metastasis Free Survival (DMFS). To evaluate the impact of radiation on clinical outcomes (OS, RFS, DMFS).

Treatments

Therapies

Medications

Pembrolizumab (Keytruda)

Inclusion Criteria

Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1, or 2 (However, those Participants with a performance state of 3 because they are wheel chair bound due to congenital or traumatic events more than one year before the diagnosis of Merkel cell carcinoma are eligible).

Women must not be pregnant or breast-feeding due to the unknown effects of the study drug in this setting. All women of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Women of childbearing potential, and sexually active males, on Arm A MK-3475 (pembrolizumab must use accepted and effective method(s) of contraception or abstain from sex from time of registration, while on study treatment, and continue for 120 days after the last dose of study treatment. For Participants on Arm B only receiving radiation therapy, contraception use should be per institutional standard.

Participant must have a histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (American Joint Committee on Cancer [AJCC] version 8) I-IIIb.

Stage I Participants with negative sentinel lymph node biopsy are ineligible. Participants who have a positive biopsy or for whom no biopsy was done are eligible.

Participants with distant metastatic disease (stage IV) are not eligible.

The primary tumor must have grossly negative margins (Microscopically positive margins are allowed)

Complete nodal dissection is not required for eligibility

Participants with all macroscopic Merkel cell carcinoma (either identified by physical exam or imaging) have been completely resected by surgery within 16 weeks before registration.

All Participants must have disease-free status documented by a complete physical examination and conventional imaging studies within 4-8 weeks prior to registration.

White blood count >= 2000/uL (within 4 weeks prior to randomization).

Absolute neutrophil count (ANC) >= 1000/Ul (within 4 weeks prior to randomization).

Platelets >= 75 x 10^3/uL (within 4 weeks prior to randomization). Hemoglobin >= 8 g/dL (>= 80 g/L; may be transfused) (within 4 weeks prior to randomization).

Creatinine =>Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =>Total bilirubin =>Operative notes from Participant's surgical resection must be accessible.

Exclusion Criteria

Participant may not have a history of a distant metastatic disease. Note: loco-regional recurrent disease is acceptable, as long as this is not metastatic (prior surgery with or without radiation therapy is acceptable).

For patients with initial presentation of Merkel cell carcinoma, patient must have no previous systemic therapy or radiation therapy prior to surgery for Merkel cell carcinoma, and cannot have completed adjuvant radiation therapy for Merkel Cell Carcinoma more than 6 weeks prior to registration. Patients actively undergoing radiation therapy or having completed adjuvant radiation therapy within 6 weeks of registration are eligible, as long as resection date is within 16 weeks of registration.

Participants with inoperable disease who have received radiation are not eligible.

Participants who are human immunodeficiency virus (HIV)+ with undetectable HIV viral load are eligible provided they meet all other protocol criteria for participation.

Participants with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are eligible provided viral loads are undetectable. Participants on suppressive therapy are eligible.

Participants must not be on active immunosuppression, have a history of life threatening virus, have had other (beside non-melanoma skin cancers, or recent indolent cancers e.g.: resected low grade prostate cancer) invasive cancer diagnoses in the last two years, or have had immunotherapy of any kind within the last 2 years.

Participants must not have a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.